MARKET WIRECNBC • 3h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why TCRT Stock dropped -11.27% Today — RQD Quant Desk Flash
$1.89 -11.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.85
Alaunos Therapeutics Inc. (TCRT) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $7.8M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.85 (-2.22%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TCRT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY TCRT SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (29% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (26% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$0.79+232.9% Next Q
23
Q2 (-2Q)Grade E$2.63-13.3% Next Q
26
Q3 (-1Q)Grade E$2.28-17.1% Next Q
28
CurrentGrade E$1.89-9.4% Hist 90D α
31
Trajectory: E (23) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TCRT Turnaround Squeeze
While TCRT currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.64) and Max Pain ($1.98) forces dealer call-delta covering toward $4.73.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TCRT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TCRT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TCRT Stock dropped -11.27% Today — RQD Quant Desk Flash
Alaunos Therapeutics Inc. (TCRT) dropped -11.27% to $1.89, trading at 31% of its 52-week range ($0.72 – $4.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 31% of its 52-week range ($0.72 – $4.5) with RSI-14 at 50 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.89 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live TCRT Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TCRT)
- ✓Walkthrough of TCRT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TCRT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.88%📐 HORIZONTAL RANGE
2026-10-30O $1.84H $2.04L $1.68C $1.89VOL 771.7K
RES: $4.56SUP: $0.40SMA50: $1.64SMA200: $2.33
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TCRT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -50.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TCRT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TCRT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TCRT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TCRT)
Health Care Rank #936 of 1016
⚔️ KPRX vs TCRT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TCRT vs. KPRX, MTVA, CURX, UPC)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Alaunos Therapeutics Inc. (TCRT) ranks #936 by composite RQD confidence (31/100, grade E) and #914 by equity capitalization ($7.8M). Within this direct 5-issuer industry benchmark cohort, TCRT leads on earnings valuation at N/A trailing P/E, while TCRT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MTVA currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with TCRT at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TCRT
ACTIVE
Alaunos Therapeutics Inc. | E | 31/100 | — | — | -35.0% | -11.27% | $7.8M | Benchmark Subject |
| KPRX Kiora Pharmaceuticals Inc. | E | 32/100 | — | — | -35.0% | -25.42% | $7.8M | /kprx-vs-tcrt → |
| MTVA MetaVia Inc. | D | 47/100 | — | — | -35.0% | +4.39% | $7.8M | /mtva-vs-tcrt → |
| CURX Curanex Pharmaceuticals Inc | D- | 37/100 | — | — | -35.0% | -0.20% | $7.7M | /curx-vs-tcrt → |
| UPC Universe Pharmaceuticals Inc. (Class A) | E | 33/100 | — | 35.3% | — | -20.21% | $7.7M | /upc-vs-tcrt → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001107421In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alaunos Therapeutics Inc. (TCRT) reported GAAP revenue of $5.0K (-50.0% vs. FY2024 revenue of $10.0K , and 0.0% cumulative change since FY2023) , GAAP net income of -$4.2M, operating cash flow of -$2.9M, and free cash flow of -$3.0M (+40.3% YoY). On the balance sheet, TCRT closed FY2025 with $3.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $5.0K | -$4.2M | -$2.9M | -$3.0M | $3.0M | — |
| FY2024 (FY) | 2024-12-31 | $10.0K | -$4.7M | -$5.0M | -$5.0M | $2.8M | $0 |
| FY2023 (FY) | 2023-12-31 | $5.0K | -$4.7M | -$30.1M | -$30.1M | — | — |
3. TCRT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TCRT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Alaunos Therapeutics Inc. (NASDAQ: TCRT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.89 (-11.27% 1D, market cap $7.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TCRT ranks #936 in composite RQD confidence.
How does TCRT compare to KPRX and MTVA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TCRT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KPRX (Kiora Pharmaceuticals Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M) and MTVA (MetaVia Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M). Among the 5-stock peer group, TCRT leads on earnings multiple (N/A) while TCRT leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TCRT?
Per TCRT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001107421), Alaunos Therapeutics Inc. generated $5.0K in revenue (-50.0% YoY), -$4.2M in net income, and -$3.0M in free cash flow against $3.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TCRT trading relative to its 50-day, 200-day, and 52-week technical levels?
TCRT last traded at $1.89 (-11.27% on volume of 473,459 shares), positioning the stock +15.24% above its 50-day simple moving average ($1.64) and -18.88% below its 200-day simple moving average ($2.33). Across its 52-week range of $0.72 to $4.50, TCRT sits at the 31.0% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.65 to $2.13).
TCRT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TCRT stock moving today?
Why TCRT Stock dropped -11.27% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.